JAGX

NASD Jaguar Health, Inc.

Nov 6, 2026 · 11:55 AM ET DELAYED Market Open

$0.3998 ↓ -0.0073 (-1.79%) Trading Down from the previous close of $0.4071, $0.0222 below the day’s high of $0.4220

YTD change: -99.92%
vs 20-day SMA: -84.17%
vs 200-day SMA: -99.64%

Price ranges

Previous day

$0.3700 $0.4800

open $0.4800 close $0.4071

-$0.0729 (-15.19%)

Today

$0.3600 $0.4220

open $0.4220 now $0.3998

-$0.0222 (-5.26%)

Past week

$0.3700 $2.0400

from $2.0400 now $0.3998

-$1.6402 (-80.40%)

Past month

$0.3700 $5.3300

from $4.5300 now $0.3998

-$4.1302 (-91.17%)

This year

$0.1999 $488.8800

from $488.8800 now $0.3998

-$488.4802 (-99.92%)

Price & Performance

-2.41 (-85.56%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 100.0% away from all-time highs of $7,205,620.0000
JAGX is down 100% since the beginning of the year
JAGX is down 100% over the past 12 months
JAGX is down 91% over the past 1 month
1% of all JAGX investors are betting against JAGX

JAGX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -76.1%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-170.34

Earnings momentum N/A Quarterly EPS growth

Quarterly change N/A

Valuation

P/E ratio N/A

Enterprise value $10.0M

Beta -2.36

Balance sheet & scale

IncomeN/A

Revenue$27.8M

Cash$6.6M

Debt$18.3K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $5.6M

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,364.73	-3.76%
JNJ	Johnson & Johnson	$272.32	-1.45%
ABBV	AbbVie, Inc.	$288.24	-2.24%
MRK	Merck & Co., Inc.	$146.94	-2.27%
RHHBY	Roche Holding Ltd Sponsored ADR	$59.45	-2.45%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.